Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Trop Pediatr ; 54(6): 375-81, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18647801

ABSTRACT

OBJECTIVE: To investigate puberty in a group of thalassemic patients with delayed or arrested pubertal development and to compare the effects of hormonal and L-carnitine therapy on puberty in those patients. PATIENTS: Thirty-two -thalassemic patients with arrested or failure of puberty were enrolled for 1 year in this study. METHOD: Clinical pubertal assessment and laboratory investigations were done for all patients at the beginning, 6 months later clinical pubertal assessment was done. Patients were divided into two groups (16 each): first group received L-carnitine therapy, while the second group received hormonal therapy. Pubertal and laboratory assessment were done 6 months after hormonal and L-carnitine therapy. RESULTS: Failure of puberty was confirmed in 71.4% of boys and 33.3% of girls, while arrested puberty was observed in 28.6% of boys and 66.7% of girls. All girls had amenorrhea, primary amenorrhea in 88.9% and secondary amenorrhea in 11.1%. Menses occurred in 20% of female patients after L-carnitine therapy and in 37.5% of them after hormonal therapy. Improvement of pubertal staging was observed in 50% of males after L-carnitine therapy compared to 75% of them after hormonal therapy. While improvement of pubertal staging was seen in 90% of females after L-carnitine therapy compared to 100% of females after hormonal treatment. However, these results showed no significant difference between both groups. CONCLUSION: Delayed puberty in beta-thalassemia major is either due to failure of gonads or failure of the whole hypothalamic pituitary gonadal axis. L-carnitine as well as hormonal replacement therapy had a positive effect on puberty in the thalassemic patients. Further studies are needed to clarify the role of L-carnitine on puberty in these patients.


Subject(s)
Carnitine/therapeutic use , Estrogens/therapeutic use , Progesterone/therapeutic use , Puberty, Delayed/drug therapy , Testosterone/therapeutic use , beta-Thalassemia/complications , Adolescent , Adult , Carnitine/administration & dosage , Carnitine/pharmacology , Estrogens/administration & dosage , Estrogens/pharmacology , Female , Follow-Up Studies , Hormone Replacement Therapy , Humans , Male , Prevalence , Progesterone/administration & dosage , Progesterone/pharmacology , Puberty, Delayed/complications , Puberty, Delayed/diagnosis , Testosterone/administration & dosage , Testosterone/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...